Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
نویسندگان
چکیده
Our paper is a first attempt to evaluate the long run impact of reference pricing on pharmaceutical innovation, health and expenditures. The model is based on a dynamic game involving three types of agents: pharmaceutical firms, consumers and a regulatory entity. Pharmaceutical firms choose the level of research investment and its innovative content, then negotiate introductory prices for new drugs with the regulator. Reference pricing affects negatively the intensity of research and it also modifies the types of innovations that are brought to the market, deterring small innovations. The model is calibrated with a small data on statins in France. Our results suggest that reference pricing typically generates a decline in health, whereas discounted expenditures may decrease or increase, depending on the degree of deterrence of cost reducing innovations.
منابع مشابه
Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry1
Our paper is a rst attempt to evaluate the long run impact of reference pricing on pharmaceutical innovation, health and expenditures. The model is based on a dynamic game involving three types of agents: pharmaceutical rms, consumers and a regulatory entity. Pharmaceutical rms choose the level of research investment and its innovative content, then negotiate introductory prices for new drug...
متن کاملاخلاق و حقوق رقابت در صنعت داروسازی
The pharmaceutical industry plays an important role in every economy. Although pharmaceutical sector has distinctive economic features, like every other sector of the economy, the production and distribution of pharmaceuticals must obey competition law rules. The provisions regarding unilateral anticompetitive conduct such as discriminatory pricing, aggressive price setting, abusing a domina...
متن کاملA Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators
This article aims to define a value-based approach to pricing and reimbursement for off-patent originators using a multiple criteria decision analysis (MCDA) approach centered on a systematic analysis of current pricing and reimbursement policies in China. A drug price policy review was combined with a quantitative analysis of China's drug purchasing database. Policy preferences were identified...
متن کامل[Drug prices: how they are established and existing price control systems].
Price is one of the main barriers of access to medicines. It is therefore important to understand how prices are formed and what factors determine the amount, as well as what interventions and regulations are the most appropriate considering their effects on access, innovation, local production and other potential objectives of drug policy. Economic analysis has developed a set of market models...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of health economics
دوره 29 2 شماره
صفحات -
تاریخ انتشار 2010